ストックスクリーナーアプリを入手
0.9098
10.04%
0.083
アフターアワーズ：
.74
-0.1698
-18.66%
前日終値:
$0.8268
開ける：
$0.8268
24時間の取引高:
231.22K
Relative Volume:
3.08
時価総額：
$84.59M
収益：
$5.61M
当期純損益:
$-42.51M
株価収益率:
-1.9524
EPS:
-0.466
ネットキャッシュフロー:
$-16.86M
1週間 パフォーマンス:
+20.82%
1か月 パフォーマンス:
+39.97%
6か月 パフォーマンス:
-25.43%
1年 パフォーマンス:
-47.10%
1日の値動き範囲:
$0.8009
$0.935
1週間の範囲:
$0.7064
$0.935
52週間の値動き範囲:
$0.4912
$2.25
Citius Oncology Inc Stock (CTOR) Company Profile
Compare CTOR vs TAK, TEVA, HLN, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CTOR
Citius Oncology Inc
|
0.9098 | 75.45M | 5.61M | -42.51M | -16.86M | -0.466 |
TAK
Takeda Pharmaceutical Co Adr
|
17.63 | 55.60B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.77 | 42.81B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.70 | 43.16B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
73.79 | 30.39B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
499.73 | 21.95B | 3.17B | 1.29B | 1.01B | 27.09 |
Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-23 | アップグレード | Maxim Group | Hold → Buy |
| 2024-11-27 | 開始されました | Maxim Group | Buy |
Citius Oncology Inc (CTOR) 最新ニュース
Breakeven On The Horizon For Citius Oncology, Inc. (NASDAQ:CTOR) - simplywall.st
Citius Pharma Reports First LYMPHIR Revenue of $7.1M in Nine Months - Minichart
Citius Oncology Posts First Revenue from LYMPHIR Launch as Institutional Demand Surges 31% - Minichart
Citius Oncology (NASDAQ:CTOR) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS - marketbeat.com
Citius Oncology (CTOR) director Jonathan Peri files Form 3 showing no common shares - Stock Titan
Citius Oncology Q3 Results: Sales miss estimate by 40%, EPS inline - scanx.trade
Citius Oncology Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Citius Pharmaceuticals Reports Q3 2026 Financial Results and LYMPHIR Progress - Intellectia AI
CTOR: LYMPHIR launch drove $7.1M revenue and 31% sequential vial order growth, with broad payer access - TradingView
Citius Oncology (CTOR) grows LYMPHIR sales but posts $41M nine-month loss - Stock Titan
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update - PR Newswire
Citius Oncology (CTOR) investor reports 9.99% beneficial ownership stake - Stock Titan
Citius Oncology appoints independent director Peri to board of directors - ROI-NJ
Citius Oncology appoints Jonathan Peri to board of directors By Investing.com - Investing.com Australia
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri - Morningstar
Citius Pharmaceuticals expands Citius Oncology board to nine with appointment of Jonathan Peri - Traders Union
Form 8K Citius Oncology Inc For: 12 August By Investing.com - Investing.com Canada
Citius Oncology adds independent director to expanded board - tipranks.com
Citius Oncology Adds Jonathan Peri to Board as LYMPHIR Commercialization Advances - citybiz
Form 8K Citius Oncology Inc For: 12 August - Investing.com India
Citius Oncology appoints Jonathan Peri to board of directors - Investing.com
Citius Oncology (CTOR) Expected to Announce Earnings on Tuesday - marketbeat.com
Citius Oncology Inc (CTOR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Citius Oncology Inc expected to post a loss of 5 cents a shareEarnings Preview - TradingView
Citius Oncology of Cranford says commercial response to cancer treatment is strong - ROI-NJ
LYMPHIR orders rise 78% QoQ as Citius Oncology expands market access for CTCL treatment. - Pluang
Citius Oncology reports strong LYMPHIR U.S. launch momentum - TipRanks
Citius Oncology reports strong LYMPHIR commercial momentum - TipRanks
Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment - PR Newswire
CTOR|Citius Oncology Inc|Price:0.654|Chg%:+0.062 - TradingKey
Citius Oncology Inc (CTOR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Citius Oncology Inc (CTOR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Citius Oncology, Inc. Revenue Breakdown – NASDAQ:CTOR - TradingView
Citius Oncology Inc (CTOR) Balance Sheet - TradingKey
Citius Oncology Inc (CTOR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Citius Oncology Inc (CTOR) Income Statement - TradingKey
TradingKey - TradingKey
Citius Oncology Inc (CTOR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CTOR|Citius Oncology Inc|Price:0.562|Chg%:-0.016 - TradingKey
CTOR|Citius Oncology Inc|Price:0.570|Chg%:+0.008 - TradingKey
Citius Oncology Inc (CTOR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Citius Oncology Inc (CTOR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Citius Oncology (NASDAQ:CTOR) Stock Price Up 0.6%Here's What Happened - marketbeat.com
Citius Pharmaceuticals (CTXR) Sidoti Micro-Cap Virtual Conference Summary - Quartr
Citius Oncology expands sales team for LYMPHIR launch - Investing.com
Citius Oncology expands sales team for LYMPHIR launch By Investing.com - Investing.com Canada
Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption - Barchart.com
Citius Oncology expands LYMPHIR launch team nationwide - scanx.trade
Citius Oncology (CTOR) Plunges Over 17% as Selling Pressure MountsMarket Neutral Pair - dars.gov.et
Citius Oncology Inc. (CTOR) Q2 2026 Earnings: Significant EPS Miss with No Reported RevenueEBITDA Analysis - po-news-eg.net
Citius Oncology (Nasdaq: CTOR) sets $18M stock deal at $1.09 to back LYMPHIR launch - Stock Titan
Citius Oncology Inc (CTOR) 財務データ
収益
当期純利益
現金流量
EPS
0.79%
5.15%
大文字化:
|
ボリューム (24 時間):